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Although the potential carcinogenic risk of radiotherapy is well known, it has become clear that there is a particularly high risk of
radiation-induced breast cancer in women treated for Hodgkin’s disease at young ages. Thankfully, death from breast cancer in this
population is uncommon, but it is important to understand factors contributing to the risk, including treatment parameters, and to
develop a logical and efficient method for medical management of those at risk. In this minireview, we examine the evidence which
should inform such a management policy.
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The prognosis of patients with Hodgkin’s disease has been
improved dramatically over the last 40 years by the development
of extended field radiotherapy techniques and then by combina-
tion chemotherapy (DeVita et al, 1980; Rosenberg and Kaplan,
1985). However, long-term follow-up of survivors has demon-
strated that a price of this success has been an increased risk of
second cancers. Acute leukaemia frequently occurs in the first
decade after treatment, mainly as a consequence of chemotherapy
regimens that included an alkylating agent (Tucker et al, 1988;
Kaldor et al, 1990; Swerdlow et al, 2000). In the long term,
however, the absolute excess risks of a second solid cancer are
higher (Swerdlow et al, 2000; Ng et al, 2002b; van Leeuwen et al,
2003) and are linked mainly with radiotherapy, although for some
sites, such as lung cancer, there may be a substantial risk also from
chemotherapy (Swerdlow et al, 2000; Travis et al, 2002). Recent
reports from The Netherlands (van Leeuwen et al, 2003) and from
an international consortium of cancer registries (Travis et al, 2003)
have refined our understanding of how therapy may affect breast
cancer risk.
The relative risks of many cancers are higher if patients have
been treated for Hodgkin’s disease at a younger age (Swerdlow
et al, 2000; van Leeuwen et al, 2000; Dores et al, 2002). Thus,
although the risk of breast cancer is only about 50% increased in
most all-age studies of women with Hodgkin’s disease (van
Leeuwen et al, 1999), relative risks are far larger than this in
patients treated at young ages, especially those treated in child-
hood and adolescence (Hancock et al, 1993; Bhatia et al, 1996b);
for them this is one of the main long-term sequelae of
radiotherapy. This effect of age is unsurprising, as similar
gradients are seen in other cohorts of radiation-exposed women
(United Nations Scientific Committee on the Effects of Atomic
Radiation, 1994).
The size of risk of breast cancer found in Hodgkin’s disease
patients has varied between studies. For patients treated under age
21 years relative risks have generally been around 15–25 (Hancock
et al, 1993; Sankila et al, 1996; Wolden et al, 1998; Metayer et al,
2000; van Leeuwen et al, 2000; Dores et al, 2002), although they
have been less raised (Neglia et al, 2001) or more raised (Mauch
et al, 1996; Bhatia et al, 1996b; Aisenberg et al, 1997; Ng et al,
2002b) than this in a few studies; absolute excess risks have
generally been of the order of 20–40 per 10000 per annum.
Relative risks have been greater for patients treated at ages 10–16
than at younger or older ages (Hancock et al, 1993; Sankila et al,
1996; Bhatia et al, 1996b; Metayer et al, 2000). Differences between
study results partly reflect differences in distributions of age at
treatment, radiation dosage and duration of follow-up, but also
caution must be exercised in interpretation of studies such as that
by Bhatia (Bhatia et al, 1996b), where follow-up to a fixed end-date
is incomplete. Such incompleteness will tend to be predominantly
for subjects who have not had a second malignancy and hence will
artefactually increase apparent risks in relation to years of
successful follow-up (Donaldson and Hancock, 1996). Similarly,
estimates of cumulative risk of breast cancer after treatment at
young ages have at the extreme been estimated at 42% at 30 years
of follow-up for women treated under age 16 years in a study with
incomplete follow-up (Bhatia et al, 1996a), but studies with high-
quality follow-up have found cumulative risks of 12% at 30 years
after treatment in the Nordic countries (Sankila et al, 1996) and
16% at 25 years in the Netherlands (van Leeuwen et al, 2000) for
patients treated under age 21 years. In median 18-year follow-up of
over 500 women treated at ages under 41 years in the Dutch
cohort, only five deaths occurred from breast cancer (Aleman et al,
2003), and among 161 deaths in long-term follow-up of 494 women
treated under age 51 years in the US, four were from breast cancer
(Ng et al, 2002a)
Risks of second primary breast cancer are also raised after
treatment for Hodgkin’s disease in young adulthood, although
relative risks are lower than those for childhood and adolescent
treatment (Hancock et al, 1993; van Leeuwen et al, 2000; Ng et al,
2002b), reflecting the greater background rates at older ages.
However, a lesser relative risk does not necessarily imply a lesser
absolute excess, and indeed van Leeuwen et al (2000) in the
Netherlands and Hancock et al (1993)and Ng et al (2002b) in the
US found absolute excess risks fairly similar for patients treated at
ages 20–29 years to those for patients treated under age 20 years.
For treatment at ages 30 years and above, most studies have found
no raised risk (Hancock et al, 1993; Aisenberg et al, 1997;
Swerdlow et al, 2000), although in a large Dutch cohort there was a
relative risk of 2.4 (0.9–5.2) for patients treated at ages 31–39
Received 17 July 2003; revised 15 October 2003; accepted 27 October
2003
*Correspondence: Professor A Horwich; E-mail: alan.horwich@icr.ac.uk
British Journal of Cancer (2004) 90, 294–298
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $25.00
www.bjcancer.comyears (van Leeuwen et al, 2000) and in a US cohort there were
relative risks of 3.7 (1.0–9.5) for women treated at 30–35 years
and 3.4 (0.4–12.1) for those treated at 36–40 years) (Ng et al,
2002b) It thus seems possible that the raised risks extend a little
beyond age 30 years, but it is unclear how far.
The cause of the raised risk of breast cancer patients treated for
Hodgkin’s disease is exposure to radiotherapy fields that involve
the breast. Most of the data discussed above, however, relate to
women treated for Hodgkin’s disease overall, and thus risks are
greater if only patients exposed to radiotherapy are considered.
For instance, in a UK cohort (Swerdlow et al, 2000) the relative risk
of breast cancer for women treated under age 25 years was 7.7, but
for those treated by radiotherapy alone at these ages it was 14.4.
In adults, at least, the induction period before breast cancer is
observed is long, with significantly raised risks appearing only at
10–14 (Swerdlow et al, 2000; Dores et al, 2002; Ng et al, 2002b) or
15–19 (Hancock et al, 1993; van Leeuwen et al, 2000) years after
first treatment. After childhood or adolescent treatment, however,
induction periods appear to be shorter (Bhatia et al, 1996b; Sankila
et al, 1996; Travis et al, 1996; Metayer et al, 2000), indeed as short
as within the first 5 years in one study (Bhatia et al, 1996b).
As a consequence of the long induction periods in adults, the
great majority of breast cancers after Hodgkin’s disease radio-
therapy occur after age 30 years. How long the risks remain raised
is as yet unknown, because of the limited length of follow-up yet
available in published studies. Several groups have presented data
for 20 and more years of follow-up, finding large and significant
relative risks of breast cancer for this time period (Hancock et al,
1993; Bhatia et al, 1996b; Wolden et al, 1998; Metayer et al, 2000;
van Leeuwen et al, 2000). One study has published cohort results
for 25 and more years, again with a significantly raised risk (Dores
et al, 2002) (in a case–control study with no general population
comparison, the risk was nonsignificantly raised at 25 and more
years for radiation-exposed women (Travis et al, 2003)). Relative
risks in these studies have usually been somewhat diminished in
the longest follow-up period compared with the period preceding
it, whereas absolute excess risks, when these have been published,
have been at least as great as in the preceding period (Hancock
et al, 1993; Wolden et al, 1998; van Leeuwen et al, 2000). Although
one cannot be sure what will occur at yet longer follow-up periods,
judging from other radiation exposed groups it would be expected
that there would be substantial raised risks persisting through 40
or more years of follow-up (Committee on the Biological Effects of
Ionizing Radiation (BEIR), 1990).
Breast cancers occurring after treatment for Hodgkin’s disease
are more likely to be bilateral than breast cancers in general
(Yahalom et al, 1992; Basu et al, 2002). There is little information
on the molecular phenotype of breast cancers after Hodgkin’s
disease; in one study 10 out of 18 tumours examined were
oestrogen receptor negative (Yahalom et al, 1992). A study of 19
tumours found no apparent difference between post-Hodgkin’s
and sporadic breast cancers in loss of heterozygosity or in TP53
and K-ras mutations, and a nonsignificantly raised frequency of
micosatellite alterations in the post-Hodgkin’s disease tumours
(Behrens et al, 2000). Two studies have described raised risk of
breast cancer in Hodgkin’s disease patients who have undergone
splenectomy or splenic irradiation (Dietrich et al, 1994; Bhatia et al,
1996b), but there are insufficient data to regard this as an
established association. Based on limited data, no clear relation has
been found with reproductive history (Travis et al, 2003).
It would be of great interest to know whether radiotherapy-
related risks interact with those from genes affecting breast cancer
susceptibility, but there is almost no information on this. Bhatia
et al (1997) found no excess of breast cancer in relatives of patients
with breast cancer after Hodgkin’s disease, but this was based on
small numbers. Because carriers of the ataxia telangiectasia (AT)
gene have increased in vitro sensitivity to radiation, and have been
found to have raised risk of breast cancer (Ramsey et al, 1996),
they might be a group for whom radiotherapy constitutes a
particular hazard. Genetic analyses of 32 patients developing
breast cancer more than 10 years after radiotherapy for Hodgkin’s
disease did not reveal evidence of truncating mutations (Broeks
et al, 2000). In a study based on AT gene sequencing which
compared HD patients with or without second breast cancers, risk
of breast cancer was not associated with either protein-truncating
or with excess missense mutations (Offit et al, 2002).
Because much of our knowledge of risk of breast cancer after
Hodgkin’s disease is derived from treatments carried out in the
1960–1980s, there is relatively little information about the likely
impact of more recent radiotherapy practices, such as involved
field radiotherapy and reduced-dose radiation. Involved field
radiation is often employed following chemotherapy in early stage
Hodgkin’s disease and is confined to overtly involved lymph nodes
plus a margin along the node chain. Clearly for presentations
confined to cervical lymph glands, breast irradiation would be
minimal, and in practice the major component of breast
irradiation derives from treating the axilla, which is a relatively
uncommon site for early Hodgkin’s disease. However, mediastinal
involvement is not uncommon and fields to the central chest will
necessarily irradiate medial breast segments. A nested case–
control study from the Netherlands (van Leeuwen et al, 2003)
included an estimate from radiotherapy charts as well as
dosimetric measurements and planning computer simulations of
radiation doses to the local area of the breast where the tumour
had developed. The risk of breast cancer increased highly
significantly with increasing radiation dose (P trend¼0.002), with
a relative risk of 4.5 (1.3–16) for X38.5Gy compared with o4Gy.
This was also shown in the international case–control study
(Travis et al, 2003) (P trend o0.001), which found a RR of 8 in
those treated to a dose of more than 40Gy to the breast, compared
with less than 4Gy. The few other studies that have investigated the
relation of risk to dosage have not calculated doses specifically to
the part of the breast in which the cancer occurred. Two studies
found evidence of a dose–response relation (Bhatia et al, 1996b;
Tinger et al, 1997) while one did not (Hancock et al, 1993),
although the great majority of person-years in the latter study were
in one dose category. There are inaccuracies in retrospective dose
allocations in such studies because radiotherapy causes breast
shrinkage, leading to changes in breast shape of treated women
over time. Nevertheless, the data from van Leeuwen’s study are
strong, and they accord with what one might expect from other
epidemiology, so it appears likely that reduction in dosage will
reduce the risk of breast cancer.
Chemotherapy alone does not appear to be associated with an
increased risk of breast cancer after Hodgkin’s disease (Swerdlow
et al, 2000; van Leeuwen et al, 2000; Dores et al, 2002), and indeed
the available data would be compatible with a reduced risk.
Analyses of patients treated with both chemotherapy and radio-
therapy have in several studies (Gervais-Fagnou et al, 1999;
Swerdlow et al, 2000; van Leeuwen et al, 2000, 2003; Travis et al,
2003) but not all (Hancock et al, 1993; Aisenberg et al, 1997)
suggested a reduced risk compared with that after radiotherapy
alone. In the British cohort, the relative risk for patients treated at
less than 25 years of age was 14.4 after radiotherapy alone and 4.6
after radiotherapy plus chemotherapy (Swerdlow et al, 2000). In
the Dutch cohort a similar reduction was seen for patients
receiving mixed therapy (van Leeuwen et al, 2003), and indeed the
effect of radiation dose on breast cancer risk was only seen in
patients who had not received chemotherapy. The diminished risk
after chemotherapy was not due to radiation dose reductions in
these patients (van Leeuwen et al, 2003). Although the diminished
risk could in principle be due to a direct effect on initiated breast
epithelial cells, it seems most likely that it is due to ovarian toxicity
and consequent hormonal ablation. A nested case–control study
from the Netherlands (van Leeuwen et al, 2003) found strong
evidence favouring hormonal ablation: 48 case patients who
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Hodgkin’s disease were compared with 175 matched controls in
whom breast cancer had not occurred. In total, 69% of controls
who had been treated with more than six cycles of chemotherapy
plus radiotherapy reached the menopause before the age of 41
years vs only 9% of controls treated with radiotherapy alone.
Reaching menopause before age 36 years was associated with a
greatly reduced risk of breast cancer (RR 0.06, 95% CI 0.01–0.45)
and risk increased steeply with number of premenopausal years
after treatment: relative risks were 0.15, 0.24 and 0.91 for o5, 5–
14, and X15 premenopausal years, respectively. Travis et al (2003)
found that breast cancer risk decreased significantly (P¼0.003)
with increasing number of alkylating agent cycles and decreased,
although the trend was not significant, with younger age at
menopause. Thus ovarian hormones may be critical to carcino-
genesis after radiation initiation. Such an effect would give a
potential explanation of why breast cancer risk decreases with
older age at irradiation, as there will be fewer or no years before
menopause in patients who are older at radiotherapy. It is notable
that after radiotherapy to the ovaries for either HD (Travis et al,
2003) or other conditions (Boice et al, 1985; Darby et al, 1994).,
there is also a reduction in risk of breast cancer, presumably
mainly due to ovarian failure, although some risk reduction has
been found even at postmenopausal ages (Boice et al, 1985; Darby
et al, 1994). For Hodgkin’s disease, the relation to chemotherapy-
induced menopause needs further investigation. Analyses of risk in
patients treated in the more recent past with chemotherapy
combinations that do not cause ovarian failure, such as
adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)
(Santoro et al, 1982), may help to clarify this issue.
What should be the clinical response to this risk, given the
admittedly incomplete data available? Breast cancer is a common
disease with more than 39000 cases per year diagnosed in the UK;
the incidence is 45 per 100000 women per annum for women aged
in their 30s rising to 300 per 100000 in those in their 80s. Thus,
even a modest increase in relative risk is of considerable concern.
Issues to consider include advising and counselling patients at
risk, the possible benefit of screening or prevention programmes,
the impact on current treatment practices for Hodgkin’s disease,
and the research needed to enable judgement and minimisation of
risk in the future. In the UK, the Department of Health is taking
steps to ensure appropriate counselling of women at risk. From
existing databases, we estimate that there are approximately 2600
women alive and at risk in Britain, although many of these may
already have been informed about their risk by physicians in their
follow-up clinics. It is important that the risk level be explained in
a readily comprehensible way and for most patients this might be
in terms of the expected excess number of breast cancers for every
100 years of follow-up as judged from individual risk factors. More
detailed risk data than currently available are needed, however,
specified by duration of follow-up, age at treatment, and dose, to
enable fully personalised advice.
There is evidence that regular mammographic screening may
reduce breast cancer mortality. However, this is derived from
screening predominantly women more than 50 years of age. In
younger women X-ray mammography may be less sensitive
because many have increased density of breast tissue, although
there is growing evidence that there is some beneficial effect
(Tabar et al, 2003). Magnetic resonance imaging is being evaluated
to screen younger women and evidence to date suggests that it is a
sensitive technique but there may be a higher false-positive rate
(Warren and Crawley, 2002). X-ray mammography involves less
than 1/1000th of the radiation dose used in treatment of Hodgkin’s
disease and can be considered for most women at increased risk.
In a US study in which Hodgkin’s disease patients underwent
mammography annually (or every second year before age 30
years), all 12 breast cancers occurring during follow-up were
evident on mammogram (Diller et al, 2002) and in another,
retrospective study, 26 out of 29 cancers were demonstrated on
mammography (Dershaw et al, 1992). Because screening needs to
start earlier than clinical cancer risk is raised if it is to serve the
purpose of early detection, it would seem reasonable that for
women who were given radiotherapy at ages 20–30 years screening
should begin at about 8–10 years postradiotherapy. For women
treated before age 20 years, it may be reasonable to add that
screening should not start before a fixed attained age – say about
25 years – because of the rarity of second primary breast cancers
before ages in the late 20s (Aisenberg et al, 1997). As to frequency
of screening, it may be reasonable to follow the procedure for
women at high genetic risk of breast cancer, and (in the UK) to
recommend annual screening up to age 50 years when the national
programme begins, and then to add an additional screening
between the three yearly national programme appointments in the
light of higher risk and desirability to limit the rate of interval
cancers.
With regard to continued use of hormone replacement therapy
(HRT) in patients with premature menopause, or hormone-based
chemopreventative strategies such as Tamoxifen for those at risk,
there are insufficient data to give clear advice. In the study by van
Leeuwen (van Leeuwen et al, 2003), risk was not significantly
increased in users of HRT, but the number of cases who had used
HRT for more than a few years was small and the confidence
interval was wide. The information on the possible protective effect
of chemotherapy discussed above suggests that hormone ablation
may reduce cancer risk, but against this must be weighed the
health benefits of HRT, for example in combating osteoporosis.
There is a case to consider a chemoprevention trial in patients at
risk of breast cancer, although patient willingness to enter such a
trial would need to be evaluated carefully to ensure there were
sufficient numbers to demonstrate whether there is an effect.
With regard to treatment of future patients, there is a need to
take account of the breast cancer risks that would arise from
radiotherapy, but to note that these apply only to a subset of all
Hodgkin’s disease patients (young women), not to all, and that a
balanced view of all the benefits and potential long-term adverse
effects needs to be taken when selecting treatment. There is a trend
in current treatment of Hodgkin’s disease toward reduced use of
radiotherapy. This comes from lack of clear evidence for overall
survival benefit in advanced and disseminated disease presenta-
tions (Specht et al, 1998). In early disease, combined modality
protocols are used in which chemotherapy is followed by involved
field radiation and doses of radiotherapy are reduced (e.g. Sieber
et al, 2000). There are limited data on chemotherapy alone in early
Hodgkin’s disease, and it is uncertain whether disease control rates
are as high as with radiotherapy or combined modality approaches
(Biti et al, 1992). A current Canadian trial is investigating ABVD in
this role. Furthermore, the advent of more sensitive response
evaluation based on positron emission tomography (Spaepen et al,
2001) may allow judgement of which patients with early Hodgkin’s
disease may completely avoid radiotherapy after initial response to
chemotherapy.
For those women who do require supradiaphragmatic radio-
therapy at ages less than 30 years, it is important to seek to
minimise dose and limit volume of breast tissue in the field and to
ensure that they are informed of, and accept, the associated risk of
second primary breast cancer.
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